(5R)-3-[6-({5-[3-(Cyclopentylsulfonyl)phenyl]-4-pentyn-1-yl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one → (5R)-3-[6-({5-[3-(Cyclopentylsulfonyl)phenyl]pentyl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
反応式
[CH:1]1([S:6]([C:9]2[CH:10]=[C:11]([C:15]#[C:16][CH2:17][CH2:18][CH2:19][O:20][CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][CH2:26][N:27]3[CH2:31][C@@H:30]([C:32]4[CH:43]=[CH:42][C:35]5[O:36][C:37]([CH3:41])([CH3:40])[O:38][CH2:39][C:34]=5[CH:33]=4)[O:29][C:28]3=[O:44])[CH:12]=[CH:13][CH:14]=2)(=[O:8])=[O:7])[CH2:5][CH2:4][CH2:3][CH2:2]1.[H][H]>CCOC(C)=O.CCO.[Pt]=O>[CH:1]1([S:6]([C:9]2[CH:10]=[C:11]([CH2:15][CH2:16][CH2:17][CH2:18][CH2:19][O:20][CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][CH2:26][N:27]3[CH2:31][C@@H:30]([C:32]4[CH:43]=[CH:42][C:35]5[O:36][C:37]([CH3:40])([CH3:41])[O:38][CH2:39][C:34]=5[CH:33]=4)[O:29][C:28]3=[O:44])[CH:12]=[CH:13][CH:14]=2)(=[O:7])=[O:8])[CH2:2][CH2:3][CH2:4][CH2:5]1参加物
6
反応物 2
生成物 1
試薬・触媒・溶媒 3
実験手順
A solution of (5R)-3-[6-({5-[3-(cyclopentylsulfonyl)phenyl]-4-pentyn-1-yl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (215 mg) in EtOAc (10 ml) and EtOH (10 ml) was hydrogenated over platinum oxide (30 mg). When hydrogen uptake had ceased the mixture was filtered through celite and the solvent was evaporated in vacuo to give the title compound (200 mg). LCMS RT=3.83 min.
後処理
- filtrationwas filtered through celite
- customthe solvent was evaporated in vacuo
出典と根拠
- ORDレコード
- ord-f2f674fec70246e0b92788b7ee45ea15
- 出典データセット
- uspto-grants-2008_10
- 特許番号
- US07442839B2
反応ノート
読み込み中…